Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 4(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04769778Phase 4Unknown

Renin Angiotensin System Blockade in Renal Transplant Patients With Presence of PECs in Urine

Role: lead

NCT01561404Phase 4Terminated

Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and Exercise

Role: lead

NCT01178450Phase 4Completed

Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation

Role: lead

NCT00396721Phase 2Completed

Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy

Role: lead

All 4 trials loaded